Slide 1: Meet AZN Management: ESC 2025
Meet AZN Management: ESC 2025 Conference call and webcast for investors and analysts 31 August 2025 1
Slide 2: Forward-looking statements
Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures.
Slide 3: Meet AZN Management @ ESC – agenda
Meet AZN Management @ ESC – agenda Furthering the AstraZeneca ambition Ruud Dobber, EVP, BioPharmaceuticals Business Addressing unmet need in Sharon Barr, EVP, BioPharmaceuticals R&D cardiometabolic diseases baxdrostat – Phase III BaxHTN: Dr Bryan Williams, Chair of Medicine, baxdrostat in hard-to-c
Slide 4: Furthering the AstraZeneca ambition
Furthering the AstraZeneca ambition Ruud Dobber EVP, BIOPHARMACEUTICALS BUSINESS
Slide 5: Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Beyond 2030 Working on “today, tomorrow and the day after" ADCs and Radioconjugates Illustrative only, not to scale Cell therapy and T-cell engagers Launching key NMEs $80bn Gene therapy AZD0120 saruparib camizestrant volrustomig Next-g
Slide 6: Addressing unmet need in cardiometabolic diseases
Addressing unmet need in cardiometabolic diseases Sharon Barr EVP, BIOPHARMACEUTICALS R&D
Slide 7: Uniquely positioned to address risk factors and interconnectedness of cardiometabolic disease
Uniquely positioned to address risk factors and interconnectedness of cardiometabolic disease Top causes of death Risk factors Blood pressure Stroke Increasing need for novel mechanisms Cholesterol and combination therapies to address multi-organ and multi-risk factor diseases Heart disease Kidney f
Slide 8: Ambition to transform care across cardiometabolic diseases where large unmet need remains
Ambition to transform care across cardiometabolic diseases where large unmet need remains Dyslipidaemia Hypertension Heart failure Kidney disease Weight management and ASCVD Address hard-to-control and amyloidosis Prevent or slow kidney and diabetes hypertension and advance failure across entire Red
Slide 9: Addressing unmet need with novel mechanisms and combinations to drive next wave of growth
Addressing unmet need with novel mechanisms and combinations to drive next wave of growth Dyslipidaemia Hypertension Heart failure Kidney disease Weight management and ASCVD and amyloidosis and diabetes laroprovstat baxdrostat Wainua baxdrostat/dapa AZD5004 oPCSK9 ASI TTR silencer ASI/SGLT2i oGLP-1
Slide 10: baxdrostat – potential first-in-class opportunity in hard-to-control hypertension
baxdrostat – potential first-in-class opportunity to set foundation in hard-to-control hypertension Significant proportion of Addressing critical unmet need by targeting patients remain uncontrolled aldosterone dysregulation with baxdrostat Highly selective, Robust safety 24-hour control 1.3bn poten
Slide 11: baxdrostat – Phase III BaxHTN
baxdrostat – Phase III BaxHTN Dr Bryan Williams CHAIR OF MEDICINE, UNIVERSITY COLLEGE LONDON
Slide 12: Background
Background ― Patients with uncontrolled and resistant hypertension are at high risk of cardiovascular morbidity and mortality and adverse renal outcomes1-4 ― Aldosterone dysregulation is a key driver of uncontrolled and resistant hypertension and hypertension-mediated organ damage5-7 ― MRAs can bloc
Slide 13: Phase III trial design
Phase III trial design standard-of-care standard-of-care R Seated SBP: placebo QD 1:4 ≥140 to <170 mmHg Uncontrolled HTN: R baxdrostat R baxdrostat 2 AHT placebo 4:1 1:1:1 1mg QD 2mg QD —or— baxdrostat R baxdrostat 2mg QD 2:1 2mg QD Resistant HTN: ≥3 AHT baxdrostat R 1:0 placebo QD 2mg QD Screening
Slide 14: Trial population
Trial population Adults ≥18 years of age with uncontrolled or resistant hypertension Key inclusion criteria Key exclusion criteria ― Mean seated-SBP ≥140 and <170 mmHg despite ― Current use of MRAs or potassium-sparing diuretics treatment with maximally tolerated doses of either ― Secondary hyperten
Slide 15: Trial endpoints
Trial endpoints Primary endpoint: change in seated office systolic BP from baseline to Week 12 ― 98% power to detect a mean (SD) difference of 6 (15) mmHg for a change from baseline in seated-SBP at Week 12 in favour of baxdrostat (1mg or 2mg versus placebo) Secondary endpoints (hierarchical order):
Slide 16: Trial disposition – primary outcome
Trial disposition – primary outcome 12-week double-blind period 2591 patients screened 1482 failed screening before placebo run-in 1109 entered 2-week placebo run-in period 313 failed screening during placebo run-in 796 randomised for 12-week double-blind treatment period 2 assigned but did not rece
Slide 17: Participant characteristics
Participant characteristics 794 participants Characteristic placebo baxdrostat 1mg baxdrostat 2mg 27% uncontrolled HTN (n=264) (n=264) (n=266) 73% resistant HTN Age, mean ± SD, years 61.9 ± 11.6 59.8 ± 11.8 61.8 ± 11.7 Male sex, n (%) 162 (61.4) 169 (64.0) 163 (61.3) ― Participants were 62% male and
Slide 18: Participant characteristics
Participant characteristics placebo baxdrostat baxdrostat Characteristic 1mg 2mg ― Clinical characteristics at baseline were (n=264) (n=264) (n=266) similar across treatment arms Seated BP, mmHg* ― Baseline BP: 149/87 mmHg Systolic, mean ± SD 149.0 ± 8.7 149.7 ± 10.1 149.1 ± 9.1 ― Median number of b
Slide 19: Primary outcome – change in seated-SBP
Primary outcome – change in seated-SBP baxdrostat versus placebo, baseline to Week 12 Change from baseline to 0 Week 12, mmHg (95% CI): -2 LSM change ± SE, mmHg -4 -6 -5.8 (-7.9, -3.8) -8 -10 -8.7 (-11.5 to -5.8; -9.8 -12 P<0.0001) (-12.6 to -7.0; -14 -14.5 (-16.5, -12.5) P<0.0001) -16 -15.7 (-17.6,
Slide 20: Changes in seated SBP at Week 12 consistent across subgroups with baxdrostat 2mg
Changes in seated SBP at Week 12 were consistent across all pre-specified subgroups with baxdrostat 2mg baxdrostat 2mg placebo Least-squares mean difference (95% CI) Subgroup n n in seated systolic blood pressure, mmHg Overall 266 263 <65 145 138 Age, years ≥65 to <75 88 91 ≥75 33 34 Female 103 102
Slide 21: Impact of 8-week randomised withdrawal period of baxdrostat 2mg on seated SBP
Impact of 8-week randomised withdrawal period of baxdrostat 2mg on seated SBP Seated-SBP at the start of the RWD period (Part 3): 133 mmHg in both groups Slow offset 6 Change from RWD baseline of effect on 4 (Week 24) to Week 32 (95% CI): baxdrostat LSM change ± SE, mmHg on SBP 2 +1.4 (-1.2, 4.0) 0
Slide 22: Impact on serum aldosterone concentrations during Part 1 and Part 3
Impact on serum aldosterone concentrations during Part 1 and Part 3 (randomised withdrawal period) Part 1: double-blind period Part 3: double-blind RWD period 12 12 10 Serum aldosterone, ng/dL 10 Serum aldosterone, ng/dL 8 8 baseline level 6 6 4 4 2 60% decrease 65% 2 decrease 0 0 0 4 Trial week 8 1
Slide 23: ABPM sub-study – 24-hour and night-time SBP versus placebo at Week 12
ABPM sub-study – baxdrostat impact on mean 24-hour and night-time SBP versus placebo at Week 12 Ambulatory 24-hour average SBP Ambulatory night-time average SBP placebo baxdrostat 1mg baxdrostat 2mg placebo baxdrostat, pooled (n=19) (n=20) (n=17) (n=19) (n=37) 15 15 +1.0 10 (-5.0 to 6.9) 10 LSM (95%
Slide 24: Safety data – Part 1 to 12 weeks
Safety data – Part 1 to 12 weeks placebo baxdrostat baxdrostat n (%) 1mg 2mg ― AEs were mostly mild (n=264) (n=264) (n=266) ― One death in the placebo group Any adverse event 109 (41.3) 125 (47.3) 119 (44.7) ― No reports of adrenal insufficiency Moderate/severe 23 (8.7) 27 (10.2) 37 (13.9) ― Most co
Slide 25: Summary
Summary ― In participants with uncontrolled or resistant hypertension, the addition of baxdrostat 1mg or 2mg once daily to background anti-hypertensive therapy led to placebo-adjusted reductions in seated-SBP of 8.7 mmHg and 9.8 mmHg, respectively, after 12 weeks of treatment ― BP responses were con
Slide 26: Delivering next-wave of CVRM growth with baxdrostat
Delivering next-wave of CVRM growth with baxdrostat Sharon Barr EVP, BIOPHARMACEUTICALS R&D Ruud Dobber EVP, BIOPHARMACEUTICALS BUSINESS
Slide 27: baxdrostat – potential first- and best-in-class aldosterone inhibitor
baxdrostat – potential first- and best-in-class aldosterone inhibitor to address hard-to-control hypertension Largest mmHg reduction Additional Differentiated profile reported in primary analysis supportive analyses Powerful aldosterone Robust Hg reduction in synthase inhibition hard-to-control popu
Slide 28: Leveraging existing foundation to transform hard-to-control hypertension globally with baxdrostat
Leveraging existing foundation to transform hard-to-control hypertension globally with baxdrostat Significant unmet Maximising strength of AstraZeneca in specialty and need across regions primary care to reach more patients with baxdrostat US: >20m c.85% >90% >115 2L+ hypertension patients of cardio
Slide 29: $5bn+ potential with baxdrostat across monotherapy and combination opportunities
$5bn+ potential with baxdrostat across monotherapy and combination opportunities Monotherapy Combination with dapagliflozin to transform treatment paradigm and to address aldosterone-driven diseases further improve cardiorenal outcomes BaxHTN Bax24 BaxPA BaxDUO-Arctic BaxDUO-Pacific PREVENT-HF hard-
Slide 30: Q&A Session
Q&A Session Key External Expert Dr Bryan Williams CHAIR OF MEDICINE, UNIVERSITY COLLEGE LONDON AstraZeneca Leadership Sharon Barr Ruud Dobber EVP, BIOPHARMACEUTICALS EVP, BIOPHARMACEUTICALS R&D BUSINESS Mikhail Kosiborod Mina Makar SVP, LATE CVRM R&D SVP, GLOBAL CVRM BUSINESS 30
Slide 31: Appendix
Appendix
Slide 32: Glossary
Glossary 2L+ second-line plus IQR interquartile range ABPM ambulatory blood pressure monitoring IRA Inflation Reduction Act ACEi angiotensin-converting enzyme inhibitor LDL-C low-density lipoprotein cholesterol ADC antibody-drug conjugate LSM least-squares mean AE adverse event M&A mergers and acqui
Slide 33: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis